ClinicalTrials.gg
CompletedNCT04678206SOOTHEUpdated Dec 13, 2021

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Phase 2 interventional study of BLU-5937 and Placebo in Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company. Completed at 116 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-12-13.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.

Enrollment
9th of 37
310 · median 50
Started
2020
with 6 others
Phase 2
16 of 44
3 open now
Registered
26th of 44
by date
Lead sponsor
4 of 44
Bellus Health Inc. - a GSK company

Among the 44 studies in Chronic Cough with a site in United States, this one is the 9th largest by enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2020, is one of 16 in phase 2, and was the 26th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Read the detailed description

The primary objective of this study is to determine the therapeutic dose of BLU-5937 in patients with refractory chronic cough by assessing the change from baseline to week 4 in the 24-hour cough frequency with BLU-5937 relative to placebo.

03

Conditions studied

  • Refractory Chronic Cough

Browse trials for

Keywords

  • BLU-5937
  • Refractory Chronic Cough
  • P2X3 receptor antagonist
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • chronic cough (including unexplained chronic cough) for at least one year
  • Women of must use a highly effective method during the study and for at least 14 days after the last dose

Exclusion criteria

Exclusion Criteria:

  • Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
  • Diagnosis of (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma
  • Respiratory tract infection within 4 weeks before screening
  • Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
  • History of in the last 5 years
  • History of alcohol or drug abuse within the last 3 years
  • Has a positive serologic test for (HIV), virus surface antigen, or virus.
  • Previous participation in a BLU-5937 trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    BLU-5937 Dose A

    BLU-5937 oral dose A twice a day.

    Drug: BLU-5937

  • Experimental
    BLU-5937 Dose B

    BLU-5937 oral dose B twice a day.

    Drug: BLU-5937

  • Experimental
    BLU-5937 Dose C

    BLU-5937 oral dose C twice a day.

    Drug: BLU-5937

  • Placebo comparator
    Placebo

    Matching Placebo for BLU-5937 oral dose twice a day.

    Drug: Placebo

  • Experimental
    BLU-5937 Dose A (Population with baseline cough < 25 coughs/hour)

    BLU-5937 oral dose A twice a day.

    Drug: BLU-5937

  • Placebo comparator
    Placebo (Population with baseline cough < 25 coughs/hour)

    Matching Placebo for BLU-5937 oral dose twice a day.

    Drug: Placebo

Interventions

  • Oral administration of BLU-5937 Tablets

  • DrugPlacebo

    Oral administration of matching placebo for BLU-5937 Tablets

06

What researchers measure

Primary outcomes

  1. Change from baseline in the 24-hour cough frequency

    Assessed using an ambulatory cough monitor

    Time frame: Week 4

Secondary outcomes

  1. Percentage of Participants with a Reduction from Baseline in the 24-hour Cough Frequency by ≥ 30%, 50% and 70%

    Assessed using an ambulatory cough monitor

    Time frame: Week 4

  2. Change from Baseline in Leicester Cough Questionnaire (LCQ)

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

    Time frame: Week 4

  3. Change from baseline in cough severity

    Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analog scale where higher scores indicate worse severity.

    Time frame: Week 4

  4. Incidence (% of subjects) of treatment-emergent adverse events (TEAEs)

    Time frame: 2 Weeks after the last study medication intake

  5. Severity (mild, moderate, or severe) of treatment-emergent adverse events (TEAEs)

    Time frame: 2 Weeks after the last study medication intake

07

Study locations

116 sites
  • Phoenix Medical Research Inc
    Peoria, Arizona 85381, United States
  • Little Rock Allergy and Asthma Clinical Research Center
    Little Rock, Arkansas 21237, United States
  • Southern California Institute For Respiratory Diseases, Inc
    Los Angeles, California 90048, United States
  • Allergy and Asthma Associates of Southern California
    Mission Viejo, California 92691, United States
  • California Medical Research Associates, Inc.
    Northridge, California 91324, United States
  • Allergy Associates Medical Group Inc.
    San Diego, California 92120, United States
  • Allergy and Asthma Associates of Santa Clara Valley Research Center
    San Jose, California 95117, United States
  • Colorado Allergy and Asthma Centers
    Denver, Colorado 80230, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • Floridian Clinical Research
    Hialeah, Florida 33016, United States
  • Sweet Hope Research Specialty, Inc.
    Hialeah, Florida 33016, United States
  • Sher Allergy Specialist/Center for Cough
    Largo, Florida 33778, United States
  • Medical Research of Central Florida
    Leesburg, Florida 34748, United States
  • ProCare Clinical Research
    Miami Lakes, Florida 33014, United States
  • Central Florida Pulmonary Group PA
    Orlando, Florida 32803, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172, United States
  • IACT Health - Columbus
    Columbus, Georgia 31904, United States
  • IACT Health - Lawrenceville
    Lawrenceville, Georgia 30046, United States
  • IACT Health - Rincon
    Rincon, Georgia 31326, United States
  • Sneeze Wheeze and Itch Associates LLC
    Normal, Illinois 61761, United States
  • AES - Synexus Clinical Research US, Inc. - Evansville
    Evansville, Indiana 47714, United States
  • Abraham Research PLLC
    Fort Mitchell, Kentucky 41017, United States
  • Infinity Medical Research Inc
    North Dartmouth, Massachusetts 02747, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Minnesota Lung Center
    Woodbury, Minnesota 55125, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • University of Missouri, ENT and Allergy Center of Missouri
    Columbia, Missouri 65201, United States
  • The Clinical Research Center LLC
    Saint Louis, Missouri 63141, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68124, United States
  • Atlantic Respiratory Institute
    Summit, New Jersey 07901, United States
  • Albuquerque Clinical Trials Inc
    Albuquerque, New Mexico 87102, United States
  • CHEAR Center LLC
    Bronx, New York 10455, United States
  • American Health Research Inc
    Charlotte, North Carolina 28277, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • Bernstein Clinical Research Center Inc
    Cincinnati, Ohio 45231, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Remington Davis Inc
    Columbus, Ohio 43215, United States
  • Vital Prospects Clinical Research Institute PC
    Tulsa, Oklahoma 74136, United States
  • Clinical Research Associates Of Central Pa
    Altoona, Pennsylvania 16601, United States
  • Synexus Clinical Research US, Inc.
    Anderson, South Carolina 29621, United States
  • National Allergy and Asthma Research
    Charleston, South Carolina 29420, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Clinical Trials Center of Middle Tennessee
    Franklin, Tennessee 37067, United States
  • Pharmaceutical Research & Consulting Inc
    Dallas, Texas 75231, United States
  • El Paso Pulmonary Association
    El Paso, Texas 79902, United States
  • Village Research, LLC
    Houston, Texas 77084, United States
  • Metroplex Pulmonary and Sleep Medicine Center
    McKinney, Texas 75069, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Sherman Clinical Research
    Sherman, Texas 75092, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
  • Intermountain Clinical Research
    Draper, Utah 84020, United States
  • TPMG Lung & Sleep Specialist
    Williamsburg, Virginia 23188, United States
  • McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • Diex Recherche - Québec
    Québec, Quebec G1N 4V3, Canada
  • Clinique Spécialisée en Allergie de la Capitale
    Québec, Quebec G1V 4W2, Canada
  • Inspiration Research Limited
    Toronto, Quebec M5T 3A9, Canada
  • C I C Maurice Inc
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Diex Recherche - Victoriaville
    Victoriaville, Quebec G6P 6P6, Canada
  • MUDr. I. Cierná Peterová s.r.o.
    Brandýs Nad Labem-Stará Boleslav, Central Bohemia 250 01, Czechia
  • Pneumologie Varnsdorf S.r.o.
    Nový Bor, Liberec 473 01, Czechia
  • Plicní ambulance Rokycany s.r.o.
    Rokycany, Plzeň 33701, Czechia
  • Synexus Czech s.r.o.
    Praha, Prague 120 00, Czechia
  • MediTrial s.r.o.
    Jindřichův Hradec, South Bohemia 377 01, Czechia
  • MUDr. Jaroslav Mares - odborny lekar pro obor tuberkulosa a respiracni nemoci
    Strakonice, South Bohemia 386 01, Czechia
  • Plicni stredisko Teplice s.r.o.
    Teplice, Ústí Nad Labem 415 01, Czechia
  • Thoraxklinik-Heidelberg gGmbH
    Heidelberg, Baden-Württemberg 69126, Germany
  • Synexus Frankfurt Research Centre
    Frankfurt am main, Hessen 60313, Germany
  • IKF Pneumologie
    Frankfurt, Hessen 60596, Germany
  • Zentrum für ambulante pneumologische Forschung Marburg GbR
    Marburg, Hessen 35037, Germany
  • Ballenberger. Freytag. Wenisch - Institut fuer klinische Forschung GmbH
    Neu Isenburg, Hessen 63263, Germany
  • Kfns Klinische Forschung Schwerin
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • Universitätsklinikum Bonn
    Bonn, Nordrhein-Westfalen 53127, Germany
  • Klinische Forschung Dresden GmbH (KFGN)
    Dresden, Sachsen 01069, Germany
  • Synexus Leipzig Research Centre
    Leipzig, Sachsen 04103, Germany
  • Ärztezentrum Axel Springer Passage
    Berlin, 10969, Germany
  • Da Vinci Maganklinika
    Pécs, Baranya 7635, Hungary
  • Synexus Gyula - Magyarország Egészségügyi Szolgáltató Kft
    Gyula, Békés 5700, Hungary
  • Szent Borbála Kórház
    Tatabánya, Nograd 2800, Hungary
  • Dr. Kenessey Albert Korhaz-Rendelointezet
    Balassagyarmat, Nógrád 2660, Hungary
  • Synexus Zalaegerszeg Magyarország Egészségügyi Kft
    Zalaegerszeg, Zala 8900, Hungary
  • Synexus Budapest - Magyarország Egészségügyi Szolgáltató Kft
    Budapest, 1036, Hungary
  • Osrodek Badan Klinicznych CLINSANTE S.C. Ewa Galczak-Nowak Malgorzata Trzaska
    Bydgoszcz, Kujawsko-pomorskie 31-826, Poland
  • Medical Center Kermed
    Bydgoszcz, Kujawsko-pomorskie 85-231, Poland
  • Centrum Medyczne Bydgoszcz - PRATIA
    Bydgoszcz, Kujawsko-pomorskie 85-796, Poland
  • Synexus Polska Sp. Z o.o Oddzial w Lodzi
    Łódź, Lodzkie 90-127, Poland
  • KLIMED
    Bychawa, Lubelskie 23-100, Poland
  • Clinical Best Solutions -Lublin
    Lublin, Lubelskie 20-078, Poland
  • Centrum Alergologii Specjalistyczna Przychodnia Alergologiczna
    Lublin, Lubelskie 20-552, Poland
  • Centrum Medyczne Warszawa - PRATIA
    Warszawa, Mazowieckie 01-869, Poland
  • Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o
    Tarnów, Małopolskie 33-100, Poland
  • Prywatny Gabinet Internistyczno-Alergologiczny
    Białystok, Podlaskie 15-010, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Gdansku
    Gdansk, Pomorskie 80-382, Poland
  • Centrum Medyczne Wos i Piwowarczyk
    Kraków, Łódzkie 31-572, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Czestochowie
    Częstochowa, Śląskie 42-202, Poland
  • Ostrowieckie Centrum Medyczne Spólka Cywilna Anna Olech-Cudzik, Krzysztof Cudzik
    Ostrowiec Świętokrzyski, Świętokrzyskie 27-400, Poland
  • Synexus Midlands Clinical Research Centre
    Birmingham, England B15 2SQ, United Kingdom
  • West Walk Surgery
    Bristol, England BS37 4AX, United Kingdom

Showing the first 100 of 116 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2021, 10 months.

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 10 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Dec 21, 2020
StartActual
Dec 7, 2020
Primary completionActual
Oct 21, 2021
CompletionActual
Nov 2, 2021
Last update
Dec 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04678206
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Dec 7, 2020
Primary completion
Oct 21, 2021
Completion
Nov 2, 2021
Last update
Dec 13, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion